TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17484874

Group type: EXPERIMENTAL
Intervention: Telaprevir 450 mg every 8 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telaprevir 750 mg every 8 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telaprevir 1250 mg every 12 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telaprevir (all dosages)
Number of subjects: 0
Study: 15234692

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Bypass surgery
Number of subjects: 56
Study: 11642016

Group type: EXPERIMENTAL
Intervention: Continuous administration of Tazocin (12 g/1.5 g a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent administration of Tazocin (three injections of 4 g/0.5 g a day)
Number of subjects: 0
Study: 9738692

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 17
Study: 7802464

Group type: EXPERIMENTAL
Intervention: Weekly bolus injection of 5-FU and Leucovorin (A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 7 days continuous injection of 5-FU after bolus injection of Leucovorin (B)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5 days simultaneously continuous injection of 5-FU with Leucovorin (C)
Number of subjects: 16
Study: 3132792

Group type: EXPERIMENTAL
Intervention: buserelin (D‐Ser(TBU)6‐GnRH ethylamide)
Number of subjects: 19

Group type: COMPARATOR
Intervention: saline
Number of subjects: 19
Study: 30268114

Group type: EXPERIMENTAL
Intervention: Crowdsourced intervention including multimedia (two videos and two images) and participatory component (inviting suggestions for improvement)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Control group (no images or videos, no invitation to submit suggestions)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Crowdsourced intervention
Number of subjects: 700

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 700
Study: 27325850

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 129
Study: 24825251

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 32
Study: 23106926

Group type: EXPERIMENTAL
Intervention: Methadone or buprenorphine exposure in utero
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Maternal weight at delivery
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Estimated gestational age (EGA)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Maternal use of selective serotonin re‐uptake inhibitors (SSRIs)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Delivery type (vaginal delivery)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Infant birthweight
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Maternal nicotine use at delivery
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Days of maternal study medication received
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Maternal use of SSRIs and higher nicotine use
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Length of treatment for NAS
Number of subjects: 131
Study: 20051692

Group type: EXPERIMENTAL
Intervention: 3 million IU of recombinant interleukin-2 (rIL-2) left in the cysts after transvaginal ultrasound-guided drainage (group I) once
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 3 million IU of recombinant interleukin-2 (rIL-2) left in the cysts after transvaginal ultrasound-guided drainage (group II) twice
Number of subjects: 25
Study: 18660565

Group type: EXPERIMENTAL
Intervention: H‐CAD intervention (1 month, 30 minutes per day, 5 days a week)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: H‐CAD intervention
Number of subjects: 81

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 81
Study: 15635270

Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block with lidocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Steroid injection
Number of subjects: 60
Study: 12560431

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 287

Group type: COMPARATOR
Intervention: No diabetes
Number of subjects: 287
Study: 10225069

Group type: EXPERIMENTAL
Intervention: Epidural infusion of morphine with bupivacaine (0.10‐0.28 mg.kg‐1.h‐1)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Epidural infusion of morphine with lidocaine (0.44‐0.98 mg.kg‐1.h‐1)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study: 8952812

Group type: EXPERIMENTAL
Intervention: Thiazide diuretics alone or in combination with beta blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiazide diuretics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiazide diuretics in combination with beta blockers or ACE inhibitors
Number of subjects: 0
Study: 8519216

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of 0.5 mg captopril (n = 16)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 30
Study: 3027837

Group type: EXPERIMENTAL
Intervention: 200 mg of itraconazole per day for five days
Number of subjects: 42

Group type: COMPARATOR
Intervention: 100 mg of itraconazole per day for five days
Number of subjects: 42
Study: 31140940

Group type: EXPERIMENTAL
Intervention: 200 mg of orally administered alpha lipoic acid (ALA) once a day during the 12‐week period
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 100
Study: 28166828

Group type: EXPERIMENTAL
Intervention: Psychological support (counselling, relaxation, mindfulness-based exercises, and possibly neuropsychological rehabilitation) delivered via 4-8 meetings.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard care (educational videos related to disease management).
Number of subjects: 150
Study: 26535612

Group type: EXPERIMENTAL
Intervention: Cranberry capsules
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 24130286

Group type: EXPERIMENTAL
Intervention: InfoClinique
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Trip database
Number of subjects: 15

Group type: COMPARATOR
Intervention: InfoClinique and Trip database
Number of subjects: 15
Study: 21738622

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg daily for four weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo daily for four weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Escitalopram and age interaction
Number of subjects: 80
Study: 19565883

Group type: EXPERIMENTAL
Intervention: Fluoroquinolones anti-tuberculosis drugs (3RFT AM Ofx Pto PAS‐INH/5RFT Ofx Pto PAS‐INH)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Re-treatment regimen (3 H3R3Z3E3S3/5 H3R3E3)
Number of subjects: 154
Study: 16996612

Group type: EXPERIMENTAL
Intervention: 1% atropine eye drops once nightly for 2 years
Number of subjects: 400

Group type: COMPARATOR
Intervention: Vehicle eye drops (placebo) once nightly for 2 years
Number of subjects: 400
Study: 12507707

Group type: EXPERIMENTAL
Intervention: Adenosine infusion (50-500 microg kg(‐1) x min(‐1))
Number of subjects: 62

Group type: COMPARATOR
Intervention: Remifentanil infusion (0.05-0.5 microg kg(‐1) x min(‐1))
Number of subjects: 62
Study: 10958215

Group type: EXPERIMENTAL
Intervention: Open antireflux surgery
Number of subjects: 310

Group type: COMPARATOR
Intervention: Omeprazole therapy (40 or 60 mg)
Number of subjects: 310
Study: 8942328

Group type: EXPERIMENTAL
Intervention: Clonidine 100 micrograms
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clonidine 150 micrograms
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (0.0625% bupivacaine + sufentanil 10 micrograms)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clonidine (all doses)
Number of subjects: 45
Study: 1955716

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 6138072

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vesparax (150 mg secobarbital, 50 mg brallobarbital, 50 mg hydroxyzine)
Number of subjects: 30
Study: 31618540

Group type: EXPERIMENTAL
Intervention: Statin therapy (pravastatin)
Number of subjects: 214
Study: 28739318

Group type: EXPERIMENTAL
Intervention: Standard yearly intervention with fluoride varnish applied biannually
Number of subjects: 801

Group type: COMPARATOR
Intervention: Standard yearly intervention
Number of subjects: 801
Study: 25427656

Group type: EXPERIMENTAL
Intervention: Registered nurse‐led care management intervention
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: Program participants (n = 251)
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Control group (propensity score‐matched controls, n = 251)
Number of subjects: 1120
Study: 23438935

Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg bid
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 20803023

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus plantarum HEAL 9 and Lactobacillus paracasei 8700:2)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 272
Study: 19439594

Group type: EXPERIMENTAL
Intervention: Lidocaine (systemically administered)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (systemically administered)
Number of subjects: 0
Study: 16761831

Group type: EXPERIMENTAL
Intervention: Gastric electrical stimulation (GES) at 12 cycles/min for one week
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Gastric electrical stimulation (GES) continued after one week
Number of subjects: 11

Group type: COMPARATOR
Intervention: No stimulation after trial period
Number of subjects: 11
Study: 15277331

Group type: EXPERIMENTAL
Intervention: Losartan 50 to 100 mg/d
Number of subjects: 219

Group type: COMPARATOR
Intervention: Atenolol 50 to 100 mg/d
Number of subjects: 219

Group type: COMPARATOR
Intervention: Losartan vs Atenolol
Number of subjects: 219
Study: 11716168

Group type: EXPERIMENTAL
Intervention: 100 microg m(‐3) H2SO4
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1,000 microg m(‐3) H2SO4
Number of subjects: 13

Group type: COMPARATOR
Intervention: Air
Number of subjects: 13
Study: 9155945

Group type: EXPERIMENTAL
Intervention: Terbinafine at 250 mg/day for 12 weeks
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 118
Study: 8301727

Group type: EXPERIMENTAL
Intervention: Saphenous vein patch (VP) closure
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Obligatory vein patch (OVP) closure
Number of subjects: 136

Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 136
Study: 3291646

Group type: EXPERIMENTAL
Intervention: Propofol, 2 mg/kg-propofol infusion, 1-20 mg/min-nitrous oxide, 60-70%
Number of subjects: 120

Group type: COMPARATOR
Intervention: Thiopental, 4 mg/kg-isoflurane, 0.2-3%-nitrous oxide, 60-70% (control)
Number of subjects: 120
Study: 31955381

Group type: EXPERIMENTAL
Intervention: Referral for post-discharge medication use review
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard discharge care
Number of subjects: 59
Study: 28645953

Group type: EXPERIMENTAL
Intervention: CPR training with a practical test including feedback (T)
Number of subjects: 587

Group type: COMPARATOR
Intervention: CPR training only (O)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: CPR training with reflection and a practical test including feedback (RT)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 587
Study: 25352617

Group type: EXPERIMENTAL
Intervention: Eight-week, twice weekly, 90-minute exercise and education programme
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 55
Study: 23415171

Group type: EXPERIMENTAL
Intervention: CRAS patients with CHF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CRAS patients with CHF (after 100% oxygen administration)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control CHF patients (room air and 100% oxygen)
Number of subjects: 30
Study: 21496654

Group type: EXPERIMENTAL
Intervention: Combination of 800 mg ibuprofen and 1000 mg acetaminophen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 18071191

Group type: EXPERIMENTAL
Intervention: 100-microg misoprostol vaginal insert
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200-microg misoprostol vaginal insert
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 400-microg misoprostol vaginal insert
Number of subjects: 12

Group type: COMPARATOR
Intervention: 200-microg oral misoprostol
Number of subjects: 12
Study: 16948481

Group type: EXPERIMENTAL
Intervention: Three accumulated sessions (3 x 167 kcal)
Number of subjects: 9

Group type: COMPARATOR
Intervention: One continuous session (1 x 500 kcal)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both conditions (continuous and accumulated)
Number of subjects: 9
Study: 12541116

Group type: EXPERIMENTAL
Intervention: 300 ml 50% Gastrografin
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 400 ml 50% Gastrografin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 23
Study: 10628714

Group type: EXPERIMENTAL
Intervention: Electronic nose
Number of subjects: 19
Study: 9178481

Group type: EXPERIMENTAL
Intervention: 7.5 micrograms liquid PRP-OMPC vaccine
Number of subjects: 908

Group type: COMPARATOR
Intervention: 15.0 micrograms lyophilized PRP-OMPC vaccine
Number of subjects: 908
Study: 1489129

Group type: EXPERIMENTAL
Intervention: Aerosolized beclomethasone (5 puffs four times a day for 6 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3516262

Group type: EXPERIMENTAL
Intervention: 5-FU i.v. weekly for 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: CMF i.v. every 2 weeks for 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy after relapse (commonly with CMFVP or CMF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormonal therapy or radiation therapy as initial therapy after relapse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight increase greater than 10 kg during adjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly observation during treatment
Number of subjects: 0
Study: 31586194

Group type: EXPERIMENTAL
Intervention: Positive psychology (PP) based intervention to promote physical activity
Number of subjects: 255
Study: 29286595

Group type: EXPERIMENTAL
Intervention: Galantamine (8 mg/d) plus standard methadone maintenance treatment (TAU)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Computerized CBT plus standard methadone treatment (TAU)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Galantamine plus computerized CBT plus TAU
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo plus TAU
Number of subjects: 120
Study: 26987347

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 3883

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3883
Study: 24052094

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) at 1.5 ATA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) at 2.0 ATA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham compression
Number of subjects: 60
Study: 22930115

Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg loading dose / 10 mg maintenance dose
Number of subjects: 93

Group type: COMPARATOR
Intervention: High dose clopidogrel 150 mg maintenance dose
Number of subjects: 93
Study: 20379680

Group type: EXPERIMENTAL
Intervention: G2: composite, soft‐start technique
Number of subjects: 32

Group type: COMPARATOR
Intervention: G1: composite, conventional light curing technique (control)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: G3: amalgam/composite association (amalcomp)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: G4: resin‐modified glass ionomer cement/composite, open sandwich technique
Number of subjects: 32
Study: 17682365

Group type: EXPERIMENTAL
Intervention: Stroke education program
Number of subjects: 547

Group type: COMPARATOR
Intervention: Standard health class
Number of subjects: 547
Study: 16227416

Group type: EXPERIMENTAL
Intervention: Betamethasone premedication
Number of subjects: 355

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 355
Study: 12432337

Group type: EXPERIMENTAL
Intervention: Micronized progesterone (MP) 100 mg transvaginally 12 days/month
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA) 10 mg p.o. 12 days/month
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transdermic nor-ethisterone acetate (NETA) 0.25 mg integrated in the ethinil-estradiol patches for the last two weeks of each cycle
Number of subjects: 60
Study: 10628599

Group type: EXPERIMENTAL
Intervention: Pressure limited ventilation (peak inflation pressure ≤30 cm H2O, tidal volume ≤8 mL/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional ventilation (peak inflation pressure ≤50 cm H2O, tidal volume 10-15 mL/kg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pressure limited ventilation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 28
Study: 8533625

Group type: EXPERIMENTAL
Intervention: DSG/EE
Number of subjects: 20

Group type: COMPARATOR
Intervention: LNG/EE
Number of subjects: 20
Study: 2193377

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 329712

Group type: COMPARATOR
Intervention: Pentobarbital (50 or 150 mg) or sodium secobarbital (50 or 150 mg) or placebo
Number of subjects: 509

Group type: COMPARATOR
Intervention: Diazepam (5, 10 or 15 mg) or hydroxyzine (50, 100, or 150 mg) or placebo
Number of subjects: 509

Group type: COMPARATOR
Intervention: Morphine (5 or 10 mg) or meperidine (50 or 100 mg) or placebo
Number of subjects: 509
Study: 31260793

Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 10 mg
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 25 mg
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA)
Number of subjects: 2400
Study: 27757803

Group type: EXPERIMENTAL
Intervention: Low-dose 131I (1.1 GBq)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: High-dose 131I (3.7 GBq)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 140
Study: 25597383

Group type: EXPERIMENTAL
Intervention: sertindole
Number of subjects: 0

Group type: COMPARATOR
Intervention: clozapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: quetiapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: FGAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 0
Study: 23637733

Group type: EXPERIMENTAL
Intervention: 7.5 µg H1N1pnd09 antigen with MF59‐adjuvant (Pa7.5 µg)
Number of subjects: 207
Study: 21320303

Group type: EXPERIMENTAL
Intervention: Structured reminiscence-based education programme for care staff
Number of subjects: 306

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 306
Study: 18790032

Group type: EXPERIMENTAL
Intervention: FLZ microemulsion based gel (FLZ-MBG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Candid V gel (marketed clotrimazole gel)
Number of subjects: 0
Study: 17760633

Group type: EXPERIMENTAL
Intervention: Medial rectus muscle re-recession (n = 12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Lateral rectus muscle resection (n = 13)
Number of subjects: 25
Study: 15588296

Group type: EXPERIMENTAL
Intervention: Fibromyalgia group (n=14)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chronic low back pain group (n=10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal control group (n=6)
Number of subjects: 30
Study: 11477202

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone therapy
Number of subjects: 40
Study: 9752139

Group type: EXPERIMENTAL
Intervention: Nurse-led shared care
Number of subjects: 0
Study: 7978176

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.036 mg/kg body weight
Number of subjects: 52

Group type: COMPARATOR
Intervention: Spontaneous recovery
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Neostigmine administration timing
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Pre-reversal time
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: PTC monitoring
Number of subjects: 52
Study: 3398555

Group type: EXPERIMENTAL
Intervention: Oral dipyridamole (19 patients)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Intravenous dipyridamole (21 patients)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (18 patients)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Oral and intravenous dipyridamole
Number of subjects: 58
Study: 31985914

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.045% lotion
Number of subjects: 1614

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 1614
Study: 29486041

Group type: EXPERIMENTAL
Intervention: Meropenem-vaborbactam (2g/2g over 3 hours; n=274)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam (4g/0.5g over 30 minutes; n=276)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Meropenem-vaborbactam
Number of subjects: 550

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam
Number of subjects: 550
Study: 26658907

Group type: EXPERIMENTAL
Intervention: IV alteplase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Presence of HAS
Number of subjects: 0

Group type: COMPARATOR
Intervention: More extensive HAS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Increasing age
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proximal vs distal HAS
Number of subjects: 0

Group type: COMPARATOR
Intervention: More vs less extensive HAS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Presence vs absence of HAS
Number of subjects: 0